356 related articles for article (PubMed ID: 17804901)
1. Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
Ramamoorthy SK; Pandita R; Prakash A; Ramaswamy NV; Al Bahar S
Acta Haematol; 2007; 118(3):141-5. PubMed ID: 17804901
[TBL] [Abstract][Full Text] [Related]
2. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
Morita R; Hashino S; Sogabe S; Dazai M; Onozawa M; Izumiyama K; Kondo T; Ota S; Kobayashi S; Imamura M; Asaka M
Rinsho Ketsueki; 2004 Oct; 45(10):1105-10. PubMed ID: 15553045
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
Higashi T; Tsukada J; Kato C; Iwashige A; Mizobe T; Machida S; Morimoto H; Ogawa R; Toda Y; Tanaka Y
Am J Hematol; 2004 Jul; 76(3):275-8. PubMed ID: 15224366
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
5. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
6. A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
Janssen JJ; Berendse HW; Schuurhuis GJ; Merle PA; Ossenkoppele GJ
Am J Hematol; 2009 Oct; 84(10):679-82. PubMed ID: 19658186
[No Abstract] [Full Text] [Related]
7. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
[No Abstract] [Full Text] [Related]
8. Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib.
Irvine DA; Shepherd JD
Bone Marrow Transplant; 2009 Aug; 44(4):267-8. PubMed ID: 19234506
[No Abstract] [Full Text] [Related]
9. Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia.
Campiotti L; Grandi AM; Biotti MG; Ultori C; Solbiati F; Codari R; Venco A
Am J Hematol; 2007 Mar; 82(3):231-3. PubMed ID: 17022045
[TBL] [Abstract][Full Text] [Related]
10. Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Wassmann B; Scheuring U; Thiede C; Pfeifer H; Bornhäuser M; Griesinger F; Hochhaus A; Schleyer E; Gschaidmeier H; Hoelzer D; Ottmann OG
Bone Marrow Transplant; 2003 Apr; 31(7):611-4. PubMed ID: 12692630
[TBL] [Abstract][Full Text] [Related]
11. Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
Simpson E; O'Brien SG; Reilly JT
Clin Lab Haematol; 2006 Jun; 28(3):215-6. PubMed ID: 16706941
[No Abstract] [Full Text] [Related]
12. Imatinib mesylate as a cause of acute liver failure.
Cross TJ; Bagot C; Portmann B; Wendon J; Gillett D
Am J Hematol; 2006 Mar; 81(3):189-92. PubMed ID: 16493605
[TBL] [Abstract][Full Text] [Related]
13. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia].
Sugawara W; Endo M; Nakatuji Y; Hosokawa T; Chida S
Rinsho Ketsueki; 2003 Sep; 44(9):962-4. PubMed ID: 14577318
[TBL] [Abstract][Full Text] [Related]
15. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
16. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
[TBL] [Abstract][Full Text] [Related]
17. Isolated central nervous system blast crisis in chronic myeloid leukemia.
Rajappa S; Uppin SG; Raghunadharao D; Rao IS; Surath A
Hematol Oncol; 2004 Dec; 22(4):179-81. PubMed ID: 15995975
[TBL] [Abstract][Full Text] [Related]
18. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.
Breccia M; Nanni M; Mancini F; Russo E; Mecarocci S; Alimena G
Haematologica; 2004 Apr; 89(4):ECR11. PubMed ID: 15075103
[No Abstract] [Full Text] [Related]
20. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
Zaucha JM; Wyrowinska E; Prejzner W; Calbecka M; Hellmann A
Clin Lab Haematol; 2006 Jun; 28(3):208-10. PubMed ID: 16706939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
